CELLTAXIS LLC has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2014. It filed its patents most often in Australia, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are BENEVOLENTAI CAMBRIDGE LTD, INTRA-CELLULAR THERAPIES INC and INTRA CELLULAR THERAPIES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 7 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | United States | 2 | |
#4 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Grosswald Ralph | 7 |
#2 | Springman Eric B | 7 |
#3 | Bhatt Lopa | 6 |
#4 | Guilford William | 5 |
#5 | Duncan Gregory S | 4 |
#6 | Ahuja Sanjeev | 4 |
#7 | Roinestad Kurt | 3 |
#8 | Pugh Margaret Mccrann | 3 |
#9 | Kirkland Tom | 3 |
#10 | Springman Eric | 3 |
Publication | Filing date | Title |
---|---|---|
US2019365750A1 | Method of reducing pulmonary exacerbations in respiratory disease patients | |
AU2014249168A1 | Methods of inhibiting leukotriene A4 hydrolase |